PharmNovo starts clinical phase I studies of a drug candidate for neuropathic pain
PharmNovo AB, a Swedish pharmaceutical company developing drugs for neuropathic pain, so-called nerve pain, today announces that phase I studies of the drug candidate PN6047 have been initiated.
The drug candidate PN6047 from PharmNovo is an entirely new drug. The substance is a selective delta opioid, a so-called DORA (delta opioid receptor agonist), which, in animal models, effectively relieves nerve pain. It does so without causing the unwanted side effects of conventional opioid drugs on the market today.
During the summer, the application to start clinical studies of PN6047 was approved by the Swedish Medical Products Agency and Ethical Review Authority. On Monday, the first dose was given to humans.
The primary goal of phase I studies is to investigate the safety and tolerability of the candidate PN6047. The trials are being carried out by Clinical Trial Consultants AB (CTC, based in Uppsala, Sweden) and will include about a hundred healthy volunteers.
"We are extremely proud and happy to have achieved a milestone we have worked to reach for a very long time. Our vision is to improve the quality of life for people suffering from chronic pain. Going from preclinical to clinical development is a significant achievement for everyone involved. I want to take this opportunity to thank and congratulate our team; everyone has worked hard and been totally committed to achieving this," says Per von Mentzer, CEO of PharmNovo.
Earlier this summer, PharmNovo completed a share issue of SEK 67 million led by the investor syndicate Sciety. Karolinska Development AB also participated in the share issue. An additional SEK 6 million was added in a rights issue. The capital will be used to implement the clinical phase I studies, produce the drug substance, and continue the company's development.
For more information, please contact:
Per von Mentzer, CEO
Phone +46 705 44 32 50
Email: per.von.mentzer@pharmnovo.com
About PharmNovo
PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatment. The company's drug candidate, PN6047, has effectively reduced nerve pain in animal models in preclinical studies. The company also sees clinical potential in other areas such as migraine, anxiety/depression, and chronic cough. PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Dr. Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research at Astra Zeneca. The team comprises prominent researchers in academia and industry, and the company has an extensive international network of leading expert advisors. To learn more, visit pharmnovo.com.
Tags:
